- Previous Close
109.80 - Open
110.08 - Bid 111.51 x 1200
- Ask 111.56 x 900
- Day's Range
108.52 - 111.76 - 52 Week Range
79.31 - 115.50 - Volume
634,508 - Avg. Volume
1,920,581 - Market Cap (intraday)
60.656B - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
11.54 - EPS (TTM)
9.63 - Earnings Date Apr 29, 2025 - May 5, 2025
- Forward Dividend & Yield 2.32 (2.11%)
- Ex-Dividend Date Feb 19, 2025
- 1y Target Est
105.07
Aflac Incorporated, through its subsidiaries, engages in the provision of supplemental health and life insurance products. The company operates in two segments: Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care, whole life, and GIFT insurance products, as well as WAYS and child endowment, and Tsumitasu insurance products in Japan. The AFLAC U.S. offers accident, disability, cancer, critical illness, hospital indemnity, dental, vision, and life insurance products in the United States. The company sells its products through individual, independent corporate, and affiliated corporate agencies; banks; independent associates/career agents; and brokers. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.
www.aflac.com12,694
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AFL
View MorePerformance Overview: AFL
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AFL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AFL
View MoreValuation Measures
Market Cap
59.93B
Enterprise Value
63.24B
Trailing P/E
11.40
Forward P/E
15.27
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.24
Price/Book (mrq)
2.30
Enterprise Value/Revenue
3.31
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
28.76%
Return on Assets (ttm)
3.38%
Return on Equity (ttm)
22.64%
Revenue (ttm)
18.93B
Net Income Avi to Common (ttm)
5.44B
Diluted EPS (ttm)
9.63
Balance Sheet and Cash Flow
Total Cash (mrq)
7.83B
Total Debt/Equity (mrq)
37.80%
Levered Free Cash Flow (ttm)
4.85B